NCT04734379 (ROCKIT-1) is a Phase 2 clinical trial of Fasudil in Progressive Supranuclear Palsy, sponsored by Woolsey Pharmaceuticals.

Who is sponsoring NCT04734379?

NCT04734379 is sponsored by Woolsey Pharmaceuticals.

What drugs are being tested in NCT04734379?

Interventions in NCT04734379: Fasudil.

What condition does NCT04734379 study?

NCT04734379 studies Progressive Supranuclear Palsy, Corticobasal Syndrome.

Is NCT04734379 still recruiting?

NCT04734379 is currently status unknown. Last updated 3 June 2022.

Last reviewed 2022-06-03 · How we verify

NCT04734379: ROCKIT-1

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Rho Kinase (ROCK) Inhibitor in Tauopathies - 1

Status unknown Phase 2 Last updated 3 June 2022

What this trial tests

Phase 2 trial testing Fasudil in Progressive Supranuclear Palsy in 15 participants. Status unknown.

Timeline

22 January 2021

Primary endpoint
30 November 2022

30 November 2023

Quick facts

Lead sponsor	Woolsey Pharmaceuticals
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	15
Start date	22 January 2021
Primary completion	30 November 2022
Estimated completion	30 November 2023
Sites	1 location across United States

Drugs / interventions tested

Fasudil — full drug profile →

Conditions studied

Progressive Supranuclear Palsy — all drugs for Progressive Supranuclear Palsy →
Corticobasal Syndrome — all drugs for Corticobasal Syndrome →

Sponsor

Woolsey Pharmaceuticals — full company profile →

Who can join

Adults 35 to 80, any sex, with Progressive Supranuclear Palsy or Corticobasal Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A Phase 2a Open-Label Preliminary Safety, Tolerability, and Biomarker Study of Oral Fasudil in Patients with the 4-Repeat Tauopathies of Progressive Supranuclear Palsy-Richardson Syndrome or Corticobasal Syndrome

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets.
Gao C, Jiang J, Tan Y, Chen S. · · 2023 · cited 998× · PMID 37735487 · DOI 10.1038/s41392-023-01588-0
Tauopathies: new perspectives and challenges.
Zhang Y, Wu KM, Yang L, Dong Q, et al · · 2022 · cited 212× · PMID 35392986 · DOI 10.1186/s13024-022-00533-z
Rho-Kinase as a Target for Cancer Therapy and Its Immunotherapeutic Potential.
Kim S, Kim SA, Han J, Kim IS. · · 2021 · cited 50× · PMID 34884721 · DOI 10.3390/ijms222312916
Parkinson's disease therapy: what lies ahead?
Wolff A, Schumacher NU, Pürner D, Machetanz G, et al · · 2023 · cited 19× · PMID 37147404 · DOI 10.1007/s00702-023-02641-6
A framework for translating tauopathy therapeutics: Drug discovery to clinical trials.
Feldman HH, Cummings JL, Boxer AL, Staffaroni AM, et al · · 2024 · cited 16× · PMID 39316411 · DOI 10.1002/alz.14250
Current Advances in Mitochondrial Targeted Interventions in Alzheimer's Disease.
Sousa T, Moreira PI, Cardoso S. · · 2023 · cited 11× · PMID 37760774 · DOI 10.3390/biomedicines11092331
Androgens and NGF Mediate the Neurite-Outgrowth through Inactivation of RhoA.
Di Donato M, Bilancio A, Auricchio F, Castoria G, et al · · 2023 · cited 9× · PMID 36766714 · DOI 10.3390/cells12030373
Why Therapeutic Trials Fail in Primary Tauopathies.
Olfati N, Ghodsi H, Bayram E, Litvan I. · · 2023 · cited 5× · PMID 36670054 · DOI 10.1002/mds.29322

Verify or expand the search:

Other trials of Fasudil

Trials testing the same drug.

NCT06362707 — Fasudil Trial for Treatment of Early Alzheimer's Disease (FEAD) · Phase 2 · recruiting
NCT03792490 — Inhibition of Rho Kinase (ROCK) With Fasudil as Disease-modifying Treatment for ALS · Phase 2 · completed

Other recruiting trials for Progressive Supranuclear Palsy

Currently open trials in the same condition.

NCT06588673 — Art Therapy in Progressive Supranuclear Palsy · NA · active not recruiting
NCT06647641 — The CurePSP Genetics Program · recruiting
NCT06174948 — The Use of the CUE1/CUE1+ in People With Parkinson's Disease and Related Disorders · NA · recruiting
NCT06122662 — AMX0035 and Progressive Supranuclear Palsy · Phase 2, PHASE3 · active not recruiting
NCT05956834 — A Multi-Modal Remote Monitoring Platform for Frontotemporal Lobar Degeneration (FTLD) Syndromes · active not recruiting

Other Woolsey Pharmaceuticals trials

Trials by the same sponsor.

NCT04793659 — Fasudil fOr redUcing elopemeNt and Spatial Disorientation · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04734379 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Woolsey Pharmaceuticals
Last refreshed: 3 June 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04734379.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing